All News

These interim trial results support the ongoing phase 3 ITHACA trial.

Experts discuss emerging targets in the immunotherapy landscape and how to improve patient outcomes through innovative approaches.

Adults with underlying medical conditions, resulting in an increased risk of respiratory syncytial virus disease are more likely to be cost-effective than general age-based strategies.

Ashraf Badros, MBCHB, discussed new data from the AURIGA study presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil.

Experts discuss immunotherapy advancements and challenges of resistance, efficacy, and toxicity in patient management.

The trial is evaluating ciltacabtagene autoleucel (cilta-cel, Carvykti; Johnson & Johnson) in patients with relapsed and lenalidomide-refractory multiple myeloma.

The indication is for adult and pediatric patients aged 2 years and older with advanced or metastatic RET-mutated medullary thyroid cancer (MTC) who require systemic therapy.

Minimal residual disease has been a major topic of discussion during the IMS 2024 Annual Meeting.

Ashraf Badros, MBCHB, discussed findings from the AURIGA study being presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil.

Promising depth of response and consistent safety profile support the use of talquetamab as a combination agent.

The estimated vaccine efficacy was approximately 58%, with only 21 patients in the vaccinated group being diagnosed with mpox.

Banerjee also discussed data being presented at the International Myeloma Society 2024 Annual Meeting that he is particularly excited for this year.

Study results showed that Black women with breast cancer were more likely to die across all subtypes, with the disparity varying from 17% to 50% depending on subtype.

The CEPHEUS trial also highlights the importance of minimal residual disease (MRD) as a study end point.

Notably, of the 38 participants who remained on treatment, 37 have switched to less frequent dosing and all have maintained responses.

Using biosimilars and generics as well as getting patients connected with manufacturer copay assistance or grant programs can reduce their out-of-pocket costs.

Vitamin D supplementation improved total cholesterol levels, systolic blood pressure, diastolic blood pressure, and all glycemic parameters.

Pharmacists should be aware of workplace hazards involving sharps and, if necessary, initiate oPEP.

Dupilumab is the first biologic medicine for patients with chronic obstructive pulmonary disease to be approved in the US.

Although disease screening reached high-risk patients, uptake was low, necessitating additional incentive to participate in voluntary testing.

Xanomeline and trospium chloride is the first in a new class, offering a new approach with selectively targeting M1 and M4 receptors.

The work of Obstetrician Ignaz Semmelweis lives on in medical protocols today.

Investigators found a significant association for febrile seizures, but not with epilepsy.

As welcome as this compliance extension may be for those who qualify, it is critical they understand both their current and future regulatory obligations.

Experts discuss current knowledge and future indications for immunotherapies and CAR T in early treatment lines.

In adolescents, a comprehensive model using behavioral and MRI data had a prediction accuracy of 0.83, which was higher than single data type models.

Holistic and compassionate counseling by a pharmacist and pharmacy-interns on-duty over weekends could positively impact patient lives, especially for older adults and economically disadvantaged patients.

The authors found that asthma severity was associated with a higher risk of type 2 diabetes, with the risk increasing in line with severity, but not asthma duration.

Clayton Irvine, PharmD, MBA, MS, notes that although these options help to lower the cost of care, quick, widespread implementation remains difficult.

INCA033989 is a monoclonal antibody that selectively targets mutant calreticulin oncogenic function.